Semaglutide improves HF symptoms in patients with obesity across range of preserved EF
In the intricate landscape of cardiovascular health, a groundbreaking revelation has emerged, illuminating the unexpected prowess of Semaglutide beyond its established role in diabetes management. Recent strides in medical research have unearthed a surprising facet of this medication, its remarkable capacity to alleviate heart failure symptoms in obese patients across a spectrum of preserved ejection […]
